JP2024038034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038034A5 JP2024038034A5 JP2023216425A JP2023216425A JP2024038034A5 JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5 JP 2023216425 A JP2023216425 A JP 2023216425A JP 2023216425 A JP2023216425 A JP 2023216425A JP 2024038034 A5 JP2024038034 A5 JP 2024038034A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- antigen
- binding fragment
- durvalumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
| JP2019543851A JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Division JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038034A JP2024038034A (ja) | 2024-03-19 |
| JP2024038034A5 true JP2024038034A5 (enExample) | 2024-05-27 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (enExample) |
| EP (1) | EP3582805A4 (enExample) |
| JP (2) | JP2020507596A (enExample) |
| KR (3) | KR20230145547A (enExample) |
| CN (2) | CN110290803A (enExample) |
| AU (2) | AU2018221822A1 (enExample) |
| CA (1) | CA3052652A1 (enExample) |
| EA (1) | EA201991870A1 (enExample) |
| IL (3) | IL320916A (enExample) |
| MA (1) | MA47509A (enExample) |
| SG (1) | SG11201907211TA (enExample) |
| WO (1) | WO2018152415A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2023526400A (ja) * | 2020-05-21 | 2023-06-21 | アストラゼネカ・アクチエボラーグ | 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量 |
| WO2026003724A1 (en) * | 2024-06-25 | 2026-01-02 | Astrazeneca Ab | Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| KR20170132171A (ko) * | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 ｐｄ１ ／ ｐｄｌ１ 저해제 |
| EP3303632B2 (en) * | 2015-05-29 | 2023-05-10 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
-
2018
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en not_active Abandoned
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2708374C2 (ru) | Комбинированная терапия для лечения рака | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| JP2017537105A5 (enExample) | ||
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| RU2012140447A (ru) | Антиангиогенная терапия для лечения рака яичника | |
| JP2013520442A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2022531408A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2022509262A5 (enExample) | ||
| Wang et al. | Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway | |
| JP2020507596A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| Liu et al. | Chitooligosaccharides attenuated hepatic encephalopathy in mice through stabilizing gut–liver–brain disturbance | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| WO2020200305A1 (zh) | 一种含羟基脲的药物组合物的应用 | |
| Wang et al. | Tetrandrine alleviates macrophage activation syndrome after CAR-T cell therapy | |
| CN114081880A (zh) | 木香内酯及其衍生物在制备预防和/或治疗肠损伤的药物中的用途 | |
| Li et al. | Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection | |
| TWI798243B (zh) | 治療癌症的方法 | |
| CN103479970A (zh) | 一种治疗风湿性关节痛的外用药物 | |
| JP2020520905A5 (enExample) | ||
| TW202317183A (zh) | 藉由併用ｃｄ４７抑制物質、免疫檢查點抑制物質及標準療法之癌症治療法 | |
| Aigner et al. | Isolated hypoxic pelvic perfusion combined with electroporation is a valid alternative to traditional therapies for anal squamous cell carcinoma: a case study |